NCI-2021-06578

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab plusChemotherapy in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

There are two medical studies happening in this phase 2 trial. One is looking at a drug called Adagrasib by itself and with another immunotherapy drug called Pembrolizumab to see if they work for a variety of  Unresectable or metastatic  non-small cell lung cancers. The other study compares Adagrasib with Pembrolizumab to Pembrolizumab with chemotherapy to see which treatment works better for this specific type of lung cancer. These studies aim to find better treatments for lung cancer patients with a certain genetic mutation called KRAS G12 C.

Immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

phase 2: An advanced point of testing, where they're trying to confirm if a treatment works well.

Unresectable: Unable to be removed through surgery

metastatic: cancer that has spread from its original location or organ to other parts of the body.

non-small cell lung cancers: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

mutation: Mutation is an alteration in the genetic material of a cell or a virus that can be inherited by its descendants

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04613596

Clinical Trial Site: Einstein

To see all available clinical trials click here.